Loading clinical trials...

SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE2/PHASE3

SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.

•Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib As Conversion Therapy Versus Camrelizumab Combined with Apatinib As First-Line Therapy for Unresectable Hepatocellular Carcinoma: a Prospective, Multicenter, Open-label, Randomized Controlled Clinical Trial.

NCT06739317•Sun Yat-sen University

View on ClinicalTrials.gov

Summary

•This is a randomized, open-label, multi-center, phases 2 and phase 3 trial to evaluate the efficacy and safety of SBRT combined with Camrelizumab and Apatinib as conversion therapy versus Camrelizumab combined with Apatinib as first-Line therapy for unresectable hepatocellular carcinoma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Signed Informed Consent Form (ICF).
•Aged 18 years or older.
•Hepatocellular carcinoma confirmed by histology/cytology. Cirrhosis meets the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Diagnosis of Liver Diseases (AASLD).
•Barcelona Clinic Liver Cancer stage B or C disease, which was not amenable to radical surgery.
•ECOG Performance Status of 0 or 1.
•Child-Pugh class of A.

Exclusion Criteria

•Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously.
•Existence of active autoimmune disease or history of autoimmune disease and may relapse.
•Patients with innate or acquired immune deficiency (e.g., HIV infection).
•Known allergies to study drugs or excipients.

Locations (1)

the First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Key Dates

Start Date

January 1, 2025

Primary Completion Date

December 31, 2030

Completion Date

June 30, 2031

Last Updated

December 18, 2024

Enrollment

398

ESTIMATED participants

Conditions

Unresectable Hepatocellular Carcinoma (HCC)

Interventions

Radiation

RADIATION

First line therapy

DRUG

First line therapy

DRUG

operation

PROCEDURE

Contacts

Ming Kuang

CONTACT

+86-020-87755766 kuangm@mail.sysu.edu.cn

Lixia Xu

CONTACT

+86-020-87755766

Using Machine Learning to Identify Responders to TACE or HAIC for uHCC

NCT07368530

Unresectable Hepatocellular Carcinoma (HCC)BCLC Stage B Hepatocellular Carcinoma+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 18, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions